

Towards chemical safety assessments using solely non-animal methods: the PARC contribution

Workshop on the Commission roadmap towards phasing out animal testing for chemical safety assessments

Mirjam Luijten

11 December 2023



Co-funded by
the European Union



What is PARC?

- A public-public **Partnership** under Horizon Europe
- An initiative where the **European Union**, prepared with early involvement of **Member States and Associated Countries**, together with public partners (EU and National Risk Agencies, Universities, Public Research Organisations), commit to **jointly support the development and implementation of a programme** of research and innovation activities in relation with **the assessment of risk of chemicals**.

PARC



Public-Public

Co-Fund Budget

EU 50/50 MS,AC
400 M€

Started : 01/05/2022

Duration : 7 years

~200 Partners

29 countries

24 Member States: Austria (AT), Belgium (BE), Croatia (HR), Cyprus (CY), Czech Republic (CZ), Denmark (DK), Estonia (EE), Finland (FI), France (FR), Germany (DE), Greece (EL), Hungary (HU), Ireland (IE), Italy (IT), Latvia (LV), Lithuania (LT), Luxembourg (LU), Netherlands (NL), Poland (PL), Portugal (PT), Slovakia (SK), Slovenia (SI), Spain (ES), Sweden (SE)

3 Associated countries: Iceland (IS), Israel (IL), Norway (NO)

2 Non-associated Third countries: Switzerland (CH), United Kingdom (UK)


3 European Agencies :



PARC Objectives

Global Objective

To consolidate and strengthen the EU's R&I capacity for **chemical risk assessment** to protect human health and the environment and to contribute to a non-toxic environment and a circular economy.




See presentation on NGRAroute in session 4, part 3

OBJECTIVE
RESEARCH & INNOVATION
TOWARDS NEXT GENERATION
RISK ASSESSMENT

WP5 Hazard Assessment

➤ BfR(DE) and ANSES (FR)




Work-streams

- Substances oriented
- Endpoint oriented
- Regulatory oriented


Human Health
Environment

WP5 Hazard Assessment


The PARC Toolbox – WP5 contribution: Hazard Assessment



Substances



Methods



WP6 Innovation in regulatory risk assessment


➤ KEMI (SE) and RIVM (NL)

Protect human health and the environment; contribute to a non-toxic environment and a circular economy



Scientific basis for NGRA

Quantitative AOP networks
Mechanism-based IATAs, using
New Approach Methodologies
Multiple route exposure
workers and general population
Unintentional mixtures and real-life exposure
Health impact assessment
Across regulatory silos




Regulatory science

Driven by **regulatory needs**
Determine **feasibility**, within
existing legislations and in
the **future**
Efficiency of **existing** and
emerging methods
Data availability and quality
Across legislations
Regulatory acceptance

*Generating the best science
to answer regulatory questions*

*Ensure that science meets
regulatory needs*

T6.1 Integrated Approaches to Testing and Assessment



Towards chemical safety assessments using solely non-animal methods


- Ensure regulatory readiness of NAMs and NGRA approaches – driven by WP2
- Leverage of existing NGRA concepts, knowledge and experience
- Join forces with initiatives external to PARC



Joint workflow for NGRA



- ASPIS aims to leverage the knowledge and insights gained from designing concepts and a large variety of case studies to **operationalize** NGRA, by developing a **well-guided NGRA workflow** for safety assessment of chemicals
- This workflow serves as **guidance** on **data generation** *and* **interpretation**
- **ASPA**, the **ASPIS-initiated alternative Safety Profiling Algorithm**:
 - Defines a tiered approach on what tools/methods to use
 - At which steps to obtain and evaluate data, incl. uncertainty assessment
 - How to put data into a context of a hazard or risk assessment scenario




Take home message

PARC has a lot to offer, including:

- Essential toxicity data, to overcome gaps in knowledge → enhanced protection of public health and the environment
- A diverse range of innovative NAMs, incl. NAMs that will have a high level of regulatory readiness
- IATAs for various health effects, incl. case studies demonstrating their applicability for different regulatory problem formulations
- A workflow for human relevance assessment
- Criteria for NAMs for regulatory use
- Contributions to (pre-)validation of NAMs in multiple ways





- PARC Website : www.eu-parc.eu
- PARC Contact: PARC@anses.fr
- Coordinator: Pascal.Sanders@anses.fr
- Deputy Coordinator: Christophe.Rousselle@anses.fr

